Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Calcineurin inhibitors, such as cyclosporine and tacrolimus, have improved allograft survival in kidney organ transplantation. Indeed, they have reduced the incidence of acute rejection episodes of cadaveric allograft recipients. Although marked progression has been made in initial survival rates, long-term kidney graft survival has yet to show such encouraging results. Because CNIs are associated with adverse effects, particularly nephrotoxicity, which contribute to declining organ function and eventual graft loss. In kidney transplants, progressive allograft dysfunction has been shown to develop in as many as 94% of patients by 1 year.

Therefore, reducing or eliminating the dose of CNIs to minimize nephrotoxicity must be balanced against the maintenance of adequate immunosuppression.

Certican allows CNI dose reduction then provides renal function improvement and current PSI strategy point out that early intervention is important in managing the risk of CAN before it develops in both de novo and maintenance renal transplant recipients.

To demonstrate Certican early introduction after 1 month provides better renal function with no change of efficacy compared to standard regimen, and also prevent delayed wound healing.


Options:
A: Arm Label: TAC+MPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Enteric Coated Mycophenolate Sodium (EC-MPS), Drug: Mycophenolate mofetil (MMF), Drug: Corticosteroids, Drug: Simulect | Arm Label: TAC+Certican; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Tacrolimus, Drug: Corticosteroids, Drug: Simulect | Arm Label: CycA+Certican; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporin A, Drug: Corticosteroids, Drug: Simulect | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): CycA+Certican, TAC+Certican | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): TAC+Certican, TAC+MPA | Intervention Type: DRUG; Name: Cyclosporin A; Assigned to Arm(s): CycA+Certican | Intervention Type: DRUG; Name: Enteric Coated Mycophenolate Sodium (EC-MPS); Assigned to Arm(s): TAC+MPA | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): TAC+MPA | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): CycA+Certican, TAC+Certican, TAC+MPA | Intervention Type: DRUG; Name: Simulect; Assigned to Arm(s): CycA+Certican, TAC+Certican, TAC+MPA
B: Arm Label: A) TEST; Type: ACTIVE_COMPARATOR; Interventions: Drug: A) TEST, Drug: B) CONTROL | Arm Label: B) CONTROL; Type: EXPERIMENTAL; Interventions: Drug: A) TEST, Drug: B) CONTROL | Intervention Type: DRUG; Name: A) TEST; Assigned to Arm(s): A) TEST, B) CONTROL | Intervention Type: DRUG; Name: B) CONTROL; Assigned to Arm(s): A) TEST, B) CONTROL
C: Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Mycophenolic acid (MPA) | Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Tacrolimus, Drug: Mycophenolic acid (MPA) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Everolimus, Tacrolimus | Intervention Type: DRUG; Name: Mycophenolic acid (MPA); Assigned to Arm(s): Everolimus, Tacrolimus
D: Arm Label: Everolimus + Low dose CsA +PD; Type: EXPERIMENTAL; Interventions: Drug: Everolimus + Low dose CsA +PD | Arm Label: Myfortic+ Standard CsA + PD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Myfortic+ Standard CsA + PD | Intervention Type: DRUG; Name: Everolimus + Low dose CsA +PD; Assigned to Arm(s): Everolimus + Low dose CsA +PD | Intervention Type: DRUG; Name: Myfortic+ Standard CsA + PD; Assigned to Arm(s): Myfortic+ Standard CsA + PD

Answer: D